Background: This investigation deals with the molecular mechanism of anti-human immunodeficiency virus type 1 (HIV-1) action of pentoxifylline (PTX) [1-(5'-oxohexyl)-3,7-dimethylxanthine] a drug widely used for the treatment of conditions involving
INTRODUCTION
Human immunodeficiency virus type 1 (HIV-1) is implicated in the deadly disease acquired immune deficiency syndrome (AIDS). Identification and characterization of agents that block its replication are currently being investigated intensively. Provirus transcription is regulated by interactions of several cellular and viral transacting proteins, including NF-KB, with specific sequences in the long terminal repeat (LTR) of HIV-1 (1) . We have reported that treatment of cells with pentoxifylline (PTX) [ 1- (5 -oxohexyl) -3,7-dimethylxanthine] inhibits HIV-1 replication (2) . PTX is also widely used for the treatment of different human peripheral blood disorders. The drug down-regulates HIV-1 LTR-driven gene expression in stimulated cells through its action upon the two nuclear factor kappa B (NF-KB) motifs in the LTR (3) . The antiviral action of PTX may be due to inhibition of any one or more of at least six steps of trans-activation by NF-KB in whole cells: (1) activation of a protein kinase; (2) activation of NF-KB by kinase action upon the inactive cytoplasmic NF-KB-IKB complex; (3) NF-KB release from phosphorylated IKB; (4) translocation of NF-KB into the nucleus; (5) its 32 Molecular Medicine, Volume 1, Number 1, November 1994 interaction with the two NF-KB motifs in the HIV-1 LTR; and (6) bound NF-KB stimulation of promoter function, the end result of these steps.
NF-KB is present in most cells as an inactive complex that is activated by diverse agents such as cytokines TNF-a and interleukin-1 (IL-1) (4, 5) , phorbol ester (PMA), cAMP, protein synthesis inhibitors, lipopolysaccharides, deoxycholate, and formamide (6) (7) (8) (9) . NF-KB is also activated by double-stranded RNA (10) and the HTLV protein tax-I (11) . Activation of NF-KB is dependent on the phosphorylation of IKB, an inhibitor complexed to NF-KB in the cytoplasm (7, (12) (13) (14) . The reaction is catalyzed by various protein kinases in different cell types (15) . Mitogen-like phorbol ester (PMA)-induced activation is mediated by protein kinase C (PKC), as is induction by some cytokines such as TNF-a (16) (17) (18) (19) . Meichle et al. (20) suggested a PKC-independent physiological activation of NF-KB, and cell-specific differences in PKC-dependent activation of NF-KB are reported (21) . IL-1-induced activation of NF-KB in certain cells was mediated by cAMP-dependent protein kinase A (PKA) (9, 22) . The involvement of Raf-1 kinase in the activation of NF-KB was also reported (23) .
The inhibitors of protein kinases used in most of the above studies have overlapping actions on both PKC and PKA. Contradictory results were obtained with the frequently used inhibitors H7 [1-( 5-isoquinoline-sulfonyl) -2-methylpipirazine hydrochloride] (24) (25) (26) (27) (28) , H8 (29) , and staurosporine (20) . Effects of H7 were also dependent on the commercial source (30) . H7 may be a mixture of two isomers; some preparations have a higher concentration of one or the other (31) . Other protein kinase inhibitors were recently described that have more specific and selective inhibitory activity against PKA and PKC. Calphostin C, a secondary metabolite of the fungus Cladosporium cladosporioides, is a selective inhibitor of PKC with a reported IC50 of 0.05 ,uM, whereas the IC50 of this drug for PKA is about 50 ,uM (32, 33) . Calphostin C inhibits protein kinase C by competing for the binding site of diacylglycerol and PMA, and its action is light-dependent (34). Qatsha et al. (35) The activation reaction mediated by either kinases was analyzed by electrophoretic mobility shift assay (EMSA) using a 32P-labeled oligonucleotide carrying the wild-type NF-KB motif under conditions described previously (3). The level of active NF-KB produced in the cell-free reaction mixture was quantitated by densitometric scanning of the specific autoradiographic signals as described previously (3).
Whole Cell Experiments
To identify the specific kinase that participates in the pathway of PMA-or TNF-a-induced activation of NF-KB in whole cells, stable expression of HIV-1 LTR-driven reporter lacZ gene in 293-27-2 and transient expression of chloramphenicol acetyl transferase (CAT) gene in Jurkat cells was determined. Cells were treated with specific inducers and kinase inhibitors as described in the figure legends. In the case of 293-27-2 cells in which HIV-1 LTR-lacZ fusion gene construct was stably integrated, both NF-KB binding (by EMSA) and its influence on the reporter gene expression (by ,3-gal activity) were measured in the nuclear and cytoplasmic extracts of treated cells as previously described (3) . Unstimulated or stimulated (with PMA or TNF-a) Jurkat cells were transiently transfected with pHIV-1 LTR-CAT and treated with specific inhibitors (either calphostin C or H88) under conditions described in the figure legends. CAT activity in cell extracts was determined as described previously (3).
RESULTS
PKC-and PKA-Dependent Activation of NF-acB in a Cell-Free System A cell-free system was described for the activation catalyzed by purified PKC of NF-KB by phosphorylation of IKB in the cytoplasmic inactive NF-KB-IKB complex and release of active NF-KB (9, 16) . In this investigation we have established a similar system with a partially purified cytoplasmic NF-KB-IKB complex from unstimulated Jurkat (T lymphoid) or 293-27-2 (human embryo kidney) cells. PKC or cAMP-dependent protein kinase (PKA) was added, to activate NF-KB as measured by electrophoretic mobility shift assay (EMSA), by its specific retardation of a 32p_ labeled oligonucleotide carrying the NF-KB motif (3). Since our goal is to quantitate the level of released active NF-KB from the cytoplasmic inactive NF-KB-IKB complex, we reasoned that measurement of free NF-KB binding with its motif to be a more direct assay of the activation step These results suggest that activation of NF-KB in this cell-free system is dependent on the externally added purified PKC or PKA and the cytoplasmic extract is devoid of such enzyme activity. The characteristic nonspecific interaction of the 32P-oligonucleotide commonly observed in similar analyses with crude nuclear extracts (3) was absent in the EMSA patterns of the cell-free NF-KB activation system with fractionated cytoplasm, as previously reported (9, 16) . The PKC/PKA-catalyzed cell-free activation of NF-KB was dependent on ATP and phosphatidylserine for PKC and cAMP for PKA (data not shown).
The specificity of the binding activity was established by competition experiments with wild-type and mutant NF-KB motifs (Fig. 2) . The wild-type NF-KB oligonucleotide competed with 32P-labeled oligonucleotide for interaction with active NF-KB, whereas the mutated oligonucleotide, even at 100-fold higher concentrations, did not compete for binding.
Effects of PTX on Activation of NF-cB by PKC or PKA in a Cell-Free System The specific interaction of active NF-KB with its motif was quantitated by densitometric scanning of the radioactive signal (indicated by an arrow in Fig. 1 ) as described in Materials and Methods. Figure 3 shows activation of NF-KB by PKA (A) and PKC (B) in cell-free system with extracts from Jurkat (upper panels) and 293-27-2 (lower panels). Previous results from this laboratory demonstrated that PTX treatment of intact Jurkat and human embryo kidney (293-27-2) cells inhibits NF-KB action (3, 42) . PKC activity is about 5-to 10-fold higher than PKA in this cell-free system and this is more evident with the extract from 293-27-2 cells (Figs. 3A and 3B) . The difference in the PKC and PKA activity in the Jurkat cell-free system is in agreement with Ghosh and Baltimore (16) The specificity of the interaction of active NF-KB with 32P-oligonucleotide in the PKC-or PKA-catalyzed cell-free activation system was determined by competition experiments with nonradioactive oligonucleotides carrying the wild-type (A) or mutated (B) NF-KB motif (described in Materials and Methods). The cell-free NF-KB activation system was as described in Fig. 1 with 1 ,ug of fractionated cytoplasmic protein, 20,000 cpm of 32P-labeled oligonucleotide, 0.2 U of PKC (designated by E) plus the indicated amounts (ng/5 ,ul reaction mixture) of nonradioactive wild-type or mutant oligonucleotides.
tion of NF-KB were observed with extracts from both Jurkat (Fig. 3, upper panels) and 293-27-2 ( Fig. 3 , lower panels) cells (Fig. 3C ). This kinase inhibition by PTX is consistent with blocking of PKC/PKA activity by other established specific kinase inhibitors.
Another possibility is that PTX directly influences the binding of NF-KB (preactivated in whole cells by PMA) with its motif. We therefore prepared nuclear extracts from PMA-treated cells, which contain activated NF-KB, and determined the influence of PTX on the DNA-protein interaction in cell-free system. Figure 4 shows that PTX added to the cell-free binding reaction did not influence the binding of active NF-KB, whereas, as shown previously, PTX treatment of whole cells inhibited NF-KB interaction with its motifs in both Jurkat and 293-27-2 cells (3, 42) .
These two sets of data, in addition to the previously reported results with whole cells (2, 3, 42) suggest that at least one primary site for inhibition by PTX of HIV-1 LTR-mediated gene activation and virus replication is on the protein kinase-dependent activation of NF-KB.
Effects of Other Kinase Inhibitors upon NF-KB Activation PTX inhibited both PKC-and PKA-catalyzed activation of NF-KB in the cell-free system. But these results do not specify which of the two kinases inhibited by PTX is involved in the PMAor TNF-a-mediated activation in whole cells. Therefore, properties of some established relatively specific protein kinase inhibitors were first tested for their effects in the cell-free NF-KB activation system. They were then used to characterize specific kinase involvement in activation of NF-KB in whole cells.
Calphostin C is reported to be a specific inhibitor of protein kinase C (32,33). We examined this property of the drug in the PKC-catalyzed cell-free NF-KB activation system described previously. Figure 5A demonstrates a concentration-dependent calphostin C inhibition. The IC50 calculated from our experiments is about 0.5 ,tM, which is somewhat higher than the reported value for the drug in another assay system (0.1 ,uM). Most strikingly, the PKA-catalyzed activation of NF-KB was not affected by calphostin C even at 20-fold higher concentrations, thereby establishing the specificity of action of this drug in this system (Fig. 5A ). These concentrations of calphostin C under the specified treatment conditions did not show cytotoxic effects on the cells and were used in whole cell experiments as described below.
H88 is reported to be a specific inhibitor of cAMP-dependent protein kinase A (PKA) (37) . This differential inhibitory property of the drug was examined on the PKC-and PKA-catalyzed NF-KB activation in the cell-free system. Figure  SB demonstrates a concentration-dependent inhibition by H88 of PKA-catalyzed release of active NF-KB (IC50 about 0.1 ,uM). No significant inhibition of PKC-catalyzed activation of NF-KB by H88 at more than 500-fold higher concentrations was detected, demonstrating that H88 is a specific inhibitor of PKA-catalyzed NF-KB activation in this system (Fig. SB) .
H7 has an overlapping inhibition of both the protein kinases. The IC50's of the compound for 35 Jurkat cells were grown in RPMI-1640 medium supplemented with 1O0% fetal bovine serum under standard tissue culture conditions described above. The cells were transfected with 2.5 jig of pHIV-l LTR-CAT (12) by the DEAEdextran procedure (47) . Sixty-eight hours after transfection the cells were treated with calphostin C (A and D, under light) or H88 (B and E) at the indicated concentrations and incubated in CO2 (5%) incubator at 37°C for .5 hr. Cells were then treated with PMA (20 ng/ml; A, B, and C) or TNF-a (10 ng /ml; D, E, and F) and incubated for an additional 3.5 hr at 37°C in CO2 (5%) incubator. The cells were then harvested, extracts were prepared, and CAT activity in 10 jig (protein) of cell extracts was determined as described previously (3) . The (C) and (F) show percent inhibition of CAT activity at the indicated concentrations of the drugs in PMA-stimulated (C) or TNF-a (F)-stimulated cells. The quantitation of CAT activity was made by densitometric scanning of the autoradiographic signals. CAT activity is expressed as percentage '4C-chloramphenicol (CAP) derivatives produced per hour in the presence of 10 Atg of protein in the cell extract. CAT activity in the absence of the drug is considered as 0% inhibition.
determined from the increased binding of the factor with its motif (3). A simultaneous elevation of HIV-1 LTR-driven reporter gene product, ,B-galactosidase activity, in the same PMA-or TNF-a-treated cells was also detected. PTX inhibited these increased activities. Since PTX inhibited both PKC-and PKA-catalyzed activation of NF-KB in the cell-free system it remains unclear which kinase in whole cells is inhibited. The kinase involved was further identified by treating intact 293-27-2 with an activator in the presence of the inhibitors of PKC or PKA whose specificity had been characterized in the cell-free NF-KB activation system. The advantage of studying the influence of specific PKC inhibitor in 293-27-2 cells is the integrated fusion gene construct pHIV-LTR-lacZ which allowed us to monitor simultaneously both NF-KB interaction with its motifs and LTRdriven stably expressed reporter gene activity in 370C for an additional 3.5 hr in 5% Co2 and 95% air. An equivalent volume of DMSO was added to control plates (untreated cells). The cells were harvested and cytoplasmic and nuclear extracts were prepared as described previously (3) . NF-KB binding activity in 5 ,ug of nuclear extract were determined by EMSA and (3-galactosidase ac-13-Galactosidase tivity in 10 jig of cytoplasmic exActivity tract of control and treated cells were determined as described previously (3) . Binding activity of NF-KB was determined by densitometric scanning and integration of the specific autoradiographic signal / 0 as described in Fig. 3 (Fig. 7, upper panels) or TNF-a (Fig. 7 , lower panels)-treated cells. Calphostin C inhibited the induced level of interaction of active NF-KB with its motif and simultaneously down regulated HIV-LTR-driven reporter gene expression (Fig. 7) . The inhibition of PMA-induced activation and down regulation of reporter gene activity by calphostin C was greater (80%) than that of TNF-a (40%). As calphostin C has been characterized as a specific inhibitor of PKC (Fig. 5A) , these results suggest that both PMA-and TNF-a-induced activation of NF-KB in 293-27-2 cells was at least in part catalyzed by PKC. These results are similar to the ones observed in transiently transfected Jurkat cells (Fig. 6) The possibility that a PKA-catalyzed pathway is also involved in the activation with either PMA or TNF-a of NF-KB in whole cells was examined both in 293-27-2 and Jurkat cells by using the specific PKA inhibitor H88 (as shown in Fig. SB) . In 293-27-2 cells NF-KB interaction with its motifs and HIV-1 LTR-driven reporter gene expression were measured in PMA (Fig. 7 , upper panels)-and TNF-a (Fig. 7, lower panels) PTX is unlikely to prevent dissociation of phosphorylated IKB from NF-KB because specificity of such a mechanism would not be expected to show the similar results observed with structurally different kinase inhibitors. Inhibition of NF-KB transport into the nucleus is possible but is not involved in the cell-free system. PTX was shown not to interfere directly with the binding of active NF-KB to its motif.
As expected, PMA-induced activation of NF-KB is catalyzed by PKC. The novel aspect of these results is the role of PKC in the physiologically more relevant activation by TNF-a. PTX can inhibit PKC-catalyzed activation of NF-KB, and thus may in part provide a mechanism for the previously reported anti-NF-KB and anti-HIV-1 action of PTX (2, 3) .
We have consistently observed a lack of strict correlation between effects on NF-KB interaction with its motif versus HIV-1 promoter-driven reporter gene expression (3) . The inhibitory influence of PKC-specific calphostin C on NF-KB interaction with its motifs was about 80%, as compared with an inhibition of HIV-1 promoter function of only 30-50% (Fig. 7) . A noninhibitable basal level of NF-KB in PMA-or TNF-atreated cells might limit maximal inhibition. This is further corroborated by our observation that the basal NF-KB binding activity and HIV-1 LTRdriven reporter gene activity in unstimulated cells could not be completely eliminated by either of these PKC inhibitors. An alternative possibility is that an HIV-1 promoter activation pathway independent of NF-KB might be involved.
However, mutations in the NF-KB motifs eliminated most of the HIV-1 promoter activity, suggesting that NF-KB-mediated activation of HIV-1 LTR is the major pathway in these cells (3) .
The PKC inhibitors may also act on virus replication at other sites and activations of other trans-activators. Possible additional interventions of PTX at steps upstream of NF-KB activation by kinases was not eliminated. Diaz-Meco et al. (46) reported the involvement of a dominant negative protein kinase C subspecies in the activation of NF-KB. The mechanism of the inhibitory action of PTX on PKC and the role of different subspecies of this enzyme was not addressed in this investigation.
The results of this study support the potential of kinase C inhibitors as anti-HIV-1 drugs. The synthetic compound Go 6976, a specific inhibitor of PKC, inhibits HIV-1 induction with little cell toxicity and without the development of resistance (35) . PTX and calphostin C as well as this compound could down regulate HIV-1 gene expression and viral replication with little toxicity to cells. PKC-mediated phosphorylation of many cellular key compounds plays a major role in signal transduction. Thus inhibition of such an important cellular function will be deleterious to the cells. However, they might be used in lower noncytotoxic concentrations in combination with other agents such as Tat (trans-activator of transcription) inhibitors, in light of our recent observation on the cooperative action of the Tatinhibitor Ro24-7429 and the NF-KB inhibitor PTX to down-regulate viral gene expression (42) .
